Critical Analysis: Alaunos Therapeutics (NASDAQ:TCRT) versus PainReform (NASDAQ:PRFX)

PainReform (NASDAQ:PRFX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for PainReform and Alaunos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Alaunos Therapeutics	1	0	0	0	1.00

Insider and Institutional Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

PainReform has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.29, suggesting that its share price is 229% less volatile than the S&P 500.

Profitability

This table compares PainReform and Alaunos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Alaunos Therapeutics	N/A	-167.97%	-120.74%

Valuation and Earnings

This table compares PainReform and Alaunos Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$17,000.00	49.31	-$5.02 million	($736.66)	0.00
Alaunos Therapeutics	$10,000.00	691.36	-$4.68 million	($2.31)	-1.29

Alaunos Therapeutics has lower revenue, but higher earnings than PainReform. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Summary

PainReform beats Alaunos Therapeutics on 7 of the 10 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.